Pfizer continues to suffer from post-patent revenue issues and so continues to close plants to balance its manufacturing needs. The next plant in line to close is a facility in Puerto Rico.
Actavis keeps rolling up competitors and keeps closing up plants to help pay for the process. Come early January, a facility in California will be the next to go.
Jordan-based Hikma has been seeing huge success with its sterile drug manufacturing and is sharing some of that success downstream with a new 15-year agreement to buy sterile injectable devices from a U.S. manufacturer.
Generic drugmaker Mylan is recalling 73 lots and more than 480,000 bottles of the generic blood pressure medicine amlodipine besylate.
The Drug Quality and Security Act, approved by the Senate Monday and now awaiting the president's signature, lays out limited FDA powers to oversee the compounding pharmacy industry and kicks off the process of establishing a so-called national track-and-trace system
Netherlands-based Royal DSM has for several years been doing smaller deals to beef up its pharma contract development and manufacturing business into something more substantial. So has Canada-based Patheon. Now, the two operations will join in a deal valued at $2.6 billion that they say will make them a major force in the pharma services business with sales approaching $2 billion.
Johnson & Johnson's Janssen unit and Merck KGaA are joining the parade of companies rolling out new manufacturing facilities in China, a market that could become the world's largest in a decade.
Merck has three facilities in Puerto Rico with more than 1,000 employees, but two of those will fall in the next couple of years as the drugmaker institutes its plan to cut 20% of its workforce and $2.5 billion in costs.
GlaxoSmithKline will "proactively" build a new plant in India as it bets on growing business there to propel earnings growth. The plant will be another facility in which it uses continuous processing and adds to the £100 million the company has invested in manufacturing capcity in India in the last decade.
FierceBiotech reports today that Novartis and Novavax have had good results from early trials of new bird flu vaccines that could be used to protect against the deadly H7N9 strain.
A longtime goal of the FDA is for the industry to put in place a national system that would allow it to follow a drug product from manufacturer to pharmacy. After years of back-and-forth with the industry about how that would be done, it is about to get started.
Eli Lilly has been slashing jobs and freezing salaries as it hunkers down before it loses patent protection on its top-selling Cymbalta. But with its diabetes franchise providing a ray of sunshine during this dark period, it is ready to build on it further, proposing to spend another $700 million on new insulin related facilities worldwide.
Sandoz, the generic drug division of Novartis, has pulled two batches of tuberculosis drugs from the market in India after some packages were found to have improper doses in strips of medications.
Dendreon is again turning to manufacturing, along with slashing more jobs, in its effort to claw its way to profitability. The drugmaker sold a plant last year to save money and raise some cash but will now invest in manufacturing in hopes that production improvements will reduce operation costs.
Pfizer and the FDA are often confronted with counterfeit of the erectile dysfunction drug Viagra that may not contain an active pharmaceutical ingredient. Now FDA is warning men they may have a counterfeit drug supplement that does contain the active ingredient in the little blue pill. And it could kill them.
The third quarter wasn't pretty when it came to drug and pharmaceutical recalls. While the number of recalls fell nearly 30%, the number of units recalled was the highest in the last 5 quarters.
Alexion is again having problems with a contract filler, forcing it to recall two more lots of its rare-disease drug Soliris because of visible particles found in vials. It is the second time in about three months that the company has been in this situation.
The manufacturing problems Japan's Daiichi Sankyo acquired when it took control of generic drugmaker Ranbaxy Laboratories have been one booby trap after another: warning letters, import bans, a consent decree and a $500 million settlement with U.S. authorities.
A plant in North Carolina will be among those closed in the wake of the buyout of Actavis by Watson Pharmaceuticals last year. It is a tough break for the 310 workers at the facility but will provide some opportunity for contact manufacturers.
Consumers who purchase over-the-counter products like Tylenol online sometimes receive items that are expired, defective, or even counterfeit. Now Johnson & Johnson and Amazon are in a fight over how much the online giant should be doing to keep that from happening.